A cheap pill could revolutionize ICU care—and hardly anyone’s talking about it. A new study from McMaster University researchers reveals that an inexpensive and widely accessible drug, pantoprazole, doesn’t just prevent dangerous stomach bleeding in critically ill patients—it might actually help hospitals save thousands of dollars each year.
Published on December 1, 2025, in JAMA Network Open, this groundbreaking study is the first to quantify how pantoprazole can deliver both lifesaving and cost-saving results when used for patients on mechanical ventilators in intensive care units (ICUs). These patients, who rely on life support, are especially prone to upper gastrointestinal bleeding—a serious complication caused by stress-induced ulcers that often prolongs hospital stays and inflates healthcare costs.
“In today’s world of ever-rising healthcare expenses, it’s rare to find an approach that’s both medically effective and budget-friendly,” said Feng Xie, Professor at McMaster University’s Department of Health Research Methods, Evidence, and Impact. “Pantoprazole does both.”
The new findings expand on the large-scale REVISE (Re-evaluating the Inhibition of Stress Erosions) Trial, another McMaster-led effort that first established the drug’s clinical value in preventing gastrointestinal bleeding. That international trial spanned 68 medical centers across eight countries and involved more than 4,800 patients—a massive undertaking that laid the foundation for the current economic evaluation.
Until now, no one had clearly mapped out the financial side of prescribing this routine stomach-protection medication to patients on ventilators. The McMaster team addressed that gap by conducting a global cost-effectiveness analysis using data from the REVISE trial. They compared outcomes and healthcare resource use between patients who received pantoprazole daily and those who did not. Their results carry major implications—not just for ICU doctors, but also for pharmacists, hospital administrators, and policymakers trying to balance quality care with financial sustainability.
Senior author Deborah Cook, Professor of Medicine at McMaster and a critical care physician at St. Joseph’s Healthcare Hamilton, highlighted just how striking the findings are. “Pantoprazole only costs between 50 cents and two dollars per dose across Canada,” she explained, “yet our data show that prescribing it regularly to patients on invasive ventilation can reduce bleeding incidents and shorten both ICU and total hospital stays. In a setting as complex and expensive as the ICU, this simple low-cost intervention can significantly improve outcomes while cutting costs.”
The economic assessment—named E-REVISE—received funding from the Hamilton Academic Health Sciences Organization and the Canadian Institutes for Health Research (CIHR). The original REVISE clinical trial was also supported by CIHR, the Accelerating Clinical Trials Fund, the Physicians Services Incorporated Foundation of Ontario, the Hamilton Association of Health Sciences Organization, and the National Health and Medical Research Council of Australia.
But here’s where opinions may divide: Should hospitals immediately adopt pantoprazole as a standard preventive measure for ventilated patients, given its proven benefits and minimal cost? Or should they proceed cautiously, waiting for additional real-world economic data before reshaping ICU protocols? After all, what looks effective in controlled trials sometimes plays out differently in everyday practice.
If this study’s conclusions hold up, it could reshape ICU pharmacology, guiding global health systems toward simpler, more efficient practices. But what do you think—should low-cost drugs like pantoprazole be prioritized in critical care to save both lives and money, or is there more to consider before making that leap?
